36results about How to "Ensure efficacy" patented technology

A mandibular advancement device is disclosed. The upper jaw (12) has fitted to it an upper plate (30). The upper plate (30) is firmly received, and generally comprises a body component (32) and two opposed flange components (34), are located to be lying in an area beside and close to the posterior teeth, and particularly the buccal side of the upper posterior teeth. The leading edge (36) of the flanges (34) provide engagement surfaces complementing the engagement surfaces of the trailing edges (26) of the lower flanges (24). The relative lengths of the respective trailing edges (26) and leading edges (36) ensure that mandibular advancement is maintained over a desired range of jaw openings. The angle of inclination of the engaging edges (26, 36) provides a jaw opening path generally arcuate with the protrusive border path.

Disclosed are stable compositions which are effective as skin whitening agents, comprising alpha, beta or gamma substituted mono-, di or polyhydroxy or polycarboxy carboxylic acids; mono-, di, tri or polyhydroxy alkyl compound; and effective amounts of an inhibitor of tyrosinase and a pigmentation reversing reagent. Also disclosed are methods of forming stable compositions of the type described above.

Plasma generation system comprising a high voltage generator (20) connected to at least two electrodes (26, 28), one having a large radius of curvature, or having a plane geometry, and the other having a small radius of curvature, this high voltage generator being controlled (32, 34, 36) in such a way as to maintain constant the mean frequency of occurrence of the current discharges between the electrodes.

A therapeutic treatment device, system and method for improving administration of a temperature sensitive drug into a tissue on the body of a patient at a drug injection site are disclosed. The device includes a treatment element with a controllable heating element in temperature communicative contact with the tissue adjacent to the drug injection site. The controllable heating element is configured to heat the tissue adjacent to the drug injection site to a controllable temperature but does not heat the injected drug above a predetermined limiting temperature, above which degradation of the injected drug may occur.

A brake system (1) having a number of sub-assemblies including a foot brake pedal (14) whose two stages correspond to service and emergency modes. Pneumatic brake modules (6) are assigned to each axle and have a proportional solenoid valve EVP (9). At least one deceleration controlling UCD unit (12) receives information from the pedal related to the pedal's position and electrically controls the brake motor (31) and / or the EVP in the service and emergency modes. A pneumatic control circuit, which is actuated in the emergency mode, controls the EVP directly from the pneumatic box (19) of the pedal. The brake system (1) is suitable for articulated multi-axle rod vehicles and used, in particular, for passenger transport.

The invention discloses a series of nutritional synergism-type bean sprout fermented milk beverages and a preparation technology thereof. The bean sprout fermented milk beverages comprise bean sproutmilk, skimmed milk, white granulated sugar, glucose, lactic acid bacteria, sodium citrate and the like. The preparation method comprises the following steps of selecting raw materials, performing germination, performing grinding to obtain pulp, performing filtration, performing defatting, performing mixing, performing homogenizing, performing sterilization, performing cooling, performing inoculation, performing fermentation, performing after-ripening, performing cold storage and the like. Leuconostoc mesenteroides fermentation is used for the first time, so that the beany flavor of bean products can be weakened, and the preparation technology is simple and high in efficiency. The prepared series of fermented bean sprout milk beverages are novel vegetable protein beverages concurrently having mouth feel, flavor and health-care nutritive functions, and a favorable development idea is provided for efficient utilization of the nutrients of bean type foods such as soybeans.

The subject matter described herein relates generally to systems and methods for delivering one or more drugs to a user while applying treatment to the infused drug site. In particular, the subject matter described herein relates to device, systems and methods for drug delivery using manual pump with an infusion set that includes one or more treatment sources to improve effectiveness of the injected medicament

An electronic system generates and manages multiple knowledge bases of medical students and practitioners. The knowledge bases are organized according to and for the function of specific limited medical problems. Data regarding each problem cross-references both basic sciences and clinical courses. Users are able to create their own knowledge base with the use of teaching data, their own user generated data, and third party user generated data. Data is dynamically updated, and the knowledge bases support the future medical practice of students.

This invention is disclosing a pure ointment of traditional Chinese medicine which was invented to treat burn or scald, and infectious trauma, and its preparation. The ointment has solved a number of problems in the treatment of burn or scald, and infectious trauma, such as the high cost of current drugs, post-treatment scar, and unfavorable therapeutic effect. The advantages of this ointment include low cost, favorable therapeutic effect, short course, and without scar after treatment. Its formula is based on the weight of every five hundred portions of following ingredients: lithospermum, 4-10 portions, beeswax, 5-20 potions, insect-white wax, 5-20 portions, and lard, 450-486 portions.

The invention relates to an apparatus for the filtration of aqueous liquid that is capable of effectively removing suspended particles from aqueous liquid during a prolonged period of time without clogging of the particulate filter media and associated pressure build-up. This filtration apparatus comprises: ⋅a filtration chamber comprising an inlet opening that is located near the bottom of the filtration chamber, and an outlet opening that is located near the top of the filtration chamber; ⋅a screen covering the outlet opening of the filtration chamber; ⋅a first dosing unit that is located upstream of the filtration chamber adapted to release water-soluble components into the stream of aqueous liquid that flows from the inlet to the filtration chamber; ⋅a particulate filter media that partially fills the interior of the filtration chamber; ⋅a flow regulator that regulates the flow rate of aqueous liquid through the filtration chamber and that can operate in a high flow rate mode or a reduced flow rate mode; ⋅a timer that controls the flow regulator; wherein the timer is programmed to alternatingly switch the flow regulator from the high flow rate mode to the reduced flow rate mode.

A device and method for delivering a therapeutic substance to the body of a mammal are provided. The device includes a pump adapter, a pump, and an infusion set having a distal connector and a proximal connector. The proximal connector and the pump adapter have connecting electrical contacts which can be connected to one another in a single action when the proximal connector and pump are being secured to the pump adapter. The distal connector of the infusion set can be connected to a catheter housing, which can be secured to the mammal's skin. The distal connector and the catheter housing have additional connecting electrical contacts which can be connected to one another in a single action when connecting the distal connector to the catheter housing.

The invention relates to wine prepared from polygonatum cyrtonema. The wine is prepared from polygonatum cyrtonema compound dry extract and special-made Sanha liquor. The compound dry extract is refined by adopting a four-three-two unique method to process polygonatum cyrtonema and adopting a compound water extraction technology and a decoloring process by taking five medicinal and edible traditional Chinese medicinal materials such as polygonatum cyrtonema, the fruit of Chinese wolfberry, raspberry and poria cocos as compatibility of medicines. The special-made Sanha liquor is brewed through unique processes of a brewing technology of mixed fermentation of high quality rice and distiller's yeast and two-year low temperature storage by taking Sanha white spirit as brewing water. The wine prepared from polygonatum cyrtonema is superior in quality, high in polysaccharide content, unique in fragrance, mellow and soft in taste and unique in process. Through detection, no chemical additives are added, so that the wine prepared from polygonatum cyrtonema is a safe and reliable organic product and has remarkable health-care functions of improving the sleeping quality, improving the human immunity and sexual capacity and delaying ageing and the like if being drunk for a long time.

The invention provides radix saposhnikoviae medicinal slices and a preparation method thereof, and relates to the technical field of traditional Chinese medicines and processing thereof. The radix saposhnikoviae medicinal slices are prepared from radix saposhnikoviae, radix alangii, radix psammosilenes, radix salviae miltiorrhizae, rhizoma chuanxiong, radix paeoniae rubra and radix astragali. Theradix saposhnikoviae medicinal slices are instant, have delicate taste, are mild in gloss, stable, efficient, fast and long-lasting in efficacy, and a kind of modern preparation convenient to take. The slices have the effects of dispelling wind and relieving exterior syndromes, clearing dampness and relieving pain, relieving itching and the like, and are mainly used for treating symptoms such as wind-cold, headache and bodily pain, rheumatic arthralgia, joint pain, stomachache and diarrhoea, rubella pruritus, beginning of ulcers and the like.

A novel dosing treatment for the administration of botulinum toxin injected into the calf muscle, namely, gastrocnemius-soleus complex in a range of about 50 to about 180 units and foot muscle group comprising one or more of a group consisting of the plantar intrinsic muscles, the plantar fascia muscles and calcaneal periosteum muscles in a range of about 20 to about 90 units of a patient to treat plantar fasciitis.

The present invention relates to a solid form of a compound of Formula (I), a method for preparing the solid form, a pharmaceutical composition comprising the solid form, and the use of the solid form in the treatment of a disease involving abnormal cell proliferation or a viral infectious disease.

The present invention relates to a salt of 5-((2-ethynyl-5-isopropylpyridin-4-yl)oxy)pyrimidine-2,4-diamine and a solid form thereof, a method for preparing the solid form and a pharmaceutical composition comprising the solid form, as well as a use of the solid form for preventing or treating diseases modulated by P2X3 and / or P2X2 / 3 receptor antagonists.

An oral solid formulation includes irinotecan or a pharmaceutically acceptable salt thereof as an active ingredient, and an acidifying agent.

An intervertebral disc prosthesis (1) having at least one upper plateau (4, 4′) and at least one lower plateau (5, 5′), which are separated by two movable cores (6, 6′) whose lower face (62, 62′) and upper face (61, 61′) respectively match a concave surface (54, 54′) of the upper plateau (4, 4′) and a convex surface (44, 44′) of the lower plateau (5, 5′). An intervertebral prosthetic unit (10) is also described having an intervertebral disc prosthesis and a posterior articular prosthesis (11) provided with two adjacent and partially tangent articular blades (12, 13), which are each coupled to a vertebra (3, 3′) by coupling devices (14) and are connected by guide devices that allow them to move along a curve whose centre C3 is provided on the same side as the implantation of said coupling means.

An oral solid formulation includes irinotecan or a pharmaceutically acceptable salt thereof as an active ingredient, and an acidifying agent.

The present invention relates to a solid form of a compound of Formula (I), a method for preparing the solid form, a pharmaceutical composition comprising the solid form, and the use of the solid form in the treatment of a disease involving abnormal cell proliferation or a viral infectious disease.

The present invention relates to a microcontainer microstructure including a microcontainer film structure having a sharp tip portion and a method of manufacturing the same.

An intervertebral disc prosthesis (1) having at least one upper plateau (4, 4′) and at least one lower plateau (5, 5′), which are separated by two movable cores (6, 6′) whose lower face (62, 62′) and upper face (61, 61′) respectively match a concave surface (54, 54′) of the upper plateau (4, 4′) and a convex surface (44, 44′) of the lower plateau (5, 5′). An intervertebral prosthetic unit (10) is also described having an intervertebral disc prosthesis and a posterior articular prosthesis (11) provided with two adjacent and partially tangent articular blades (12, 13), which are each coupled to a vertebra (3, 3′) by coupling devices (14) and are connected by guide devices that allow them to move along a curve whose center C3 is provided on the same side as the implantation of said coupling means.

Provided are a nimodipine water-soluble derivative, and a preparation method and a use thereof, belonging to the field of pharmaceutical chemistry. The nimodipine water-soluble derivative has the structural feature of general formula I and has a relatively high water solubility, and can be converted into nimodipine by an internal enzyme in blood or in the body, so that the nimodipine water-soluble derivative can be used as a nimodipine prodrug and a calcium ion antagonist for treating cardiovascular and cerebrovascular diseases.

The present disclosure relates to crystalline forms of Baricitinib and processes for preparation thereof. The present disclosure also relates to pharmaceutical composition containing these crystalline forms and use of these crystalline forms for preparing JAK inhibitor drugs and preparing drugs treating rheumatoid arthritis. The crystalline forms of the present disclosure have one or more improved properties compared with crystalline forms of the prior art and have significant values for future drug optimization and development.